MeSH tree: C20.683.515.761
A new Northwestern Medicine study has discovered how radiotherapy alters the immune environment within cutaneous T-cell lymphoma (CTCL) tumors, according to findings published in the Journal of the American Academy of Dermatology.
Jul 7, 2026
0
2
Researchers led by Universitätsmedizin Frankfurt and Goethe University Frankfurt have identified how particularly aggressive forms of lymphoma can be recognized. By combining genetic and proteomic analyses, the scientists ...
Jul 3, 2026
0
6
A new study led by researchers at the University of Hawaiʻi Cancer Center found that at least $230 million was spent on cancer care delivered outside Hawaiʻi between 2021 and 2023, highlighting the significant financial impact ...
Jul 3, 2026
0
6
Survivors of hematologic cancers are at high risk of developing cardiovascular disease (CVD), according to a study published online June 22 in BMC Cancer.
Jun 30, 2026
0
4
After a median follow-up of 10 years, more than one-third of patients with large B-cell lymphoma and nearly half of patients with follicular lymphoma who received a single infusion of tisagenlecleucel—the CAR T-cell therapy ...
Jun 25, 2026
0
10
UK media celebrity Jeremy Clarkson this week revealed he has been diagnosed with an aggressive form of prostate cancer.
Jun 18, 2026
0
15
Researchers at the University of Maryland School of Medicine (UMSOM) have identified a target that may improve the response to CAR T-cell therapy, a treatment for patients with recurrent or difficult-to-treat blood cancers.
Jun 15, 2026
0
4
Scientists at Florida International University may have found a way to make a powerful cancer treatment work even better. The treatment, called CAR-T therapy, uses a patient's own immune cells to fight cancer. Doctors remove ...
Jun 13, 2026
0
10
Chimeric antigen receptor T-cell therapy, or CAR-T, has transformed treatment for blood cancers. The immunotherapy involves reprogramming a patient's own immune cells to recognize and attack tumor cells. It offers many patients ...
Jun 7, 2026
0
8
A new study has uncovered why many patients with relapsed diffuse large B-cell lymphoma (rDLBCL) fail to respond as well as expected to newly approved cancer therapies. Patients treated with novel therapies in routine practice ...
Jun 1, 2026
0
3
